Abstract:ABSTRACT Staphylococcus aureus produces numerous virulence factors, each contributing different mechanisms to bacterial pathogenesis in a spectrum of diseases. Alpha toxin (AT), a cytolytic pore-forming toxin, plays a key role in skin and soft tissue infections and pneumonia, and a human anti-AT monoclonal antibody (MAb), MEDI4893*, has been shown to reduce disease severity in dermonecrosis and pneumonia infection models. However, interstrain diversity and the complex pathogenesis of S. aureus bloodstream infections suggests that MEDI4893* alone may not provide adequate protection against S. aureus sepsis. Clumping factor A (ClfA), a fibrinogen binding protein, is an important virulence factor facilitating S. aureus bloodstream infections. Herein, we report on the identification of a high-affinity anti-ClfA MAb, 11H10, that inhibits ClfA binding to fibrinogen, prevents bacterial agglutination in human plasma, and promotes opsonophagocytic bacterial killing (OPK). 11H10 prophylaxis reduced disease severity in a mouse bacteremia model and was dependent on Fc effector function and OPK. Additionally, prophylaxis with 11H10 in combination with MEDI4893* provided enhanced strain coverage in this model and increased survival compared to that obtained with the individual MAbs. The MAb combination also reduced disease severity in murine dermonecrosis and pneumonia models, with activity similar to that of MEDI4893* alone. These results indicate that an MAb combination targeting multiple virulence factors provides benefit over a single MAb neutralizing one virulence mechanism by providing improved efficacy, broader strain coverage, and protection against multiple infection pathologies. IMPORTANCE Alternative strategies to broad-spectrum antibiotics are required to combat the antibiotic resistance epidemic. Previous attempts at active or passive immunization against Staphylococcus aureus targeting single antigens have failed in clinical trials despite positive preclinical data. To provide broad disease and isolate coverage, an effective immunization strategy likely must target multiple virulence mechanisms of the pathogen. Herein, we tested a multimechanistic MAb combination targeting alpha toxin (AT) and clumping factor A (ClfA) that neutralizes AT-mediated cytotoxicity, blocks fibrinogen binding by ClfA, prevents bacterial agglutination, targets the bacteria for opsonophagocytic killing, and provides broad isolate coverage in a lethal-bacteremia model. Although each MAb alone was effective in bacteremia against some individual isolates, the MAb combination provided improved protection against other isolates. These results illustrate the importance of targeting multiple virulence mechanisms and highlight the potential for an MAb combination targeting AT and ClfA to effectively prevent S. aureus disease.

High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation

A Human/Murine Chimeric Fab Antibody Neutralizes Anthrax Lethal ToxinIn Vitro

Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.

Gas mixing during breath holding studied by intrapulmonary gas sampling.

Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Expression of Furin-Linked Fab Fragments Against Anthrax Toxin in a Single Mammalian Expression Vector

Cloning and Expression in E. Coli of a Functional Fab Fragment Obtained from Single Human Lymphocyte Against Anthrax Toxin

Non-Gaussian clutter modeling with generalized spherically invariant random vectors

The receptors that mediate the direct lethality of anthrax toxin

SCN5A mutation associated with ventricular fibrillation, early repolarization, and concealed myocardial abnormalities.

Specific, Sensitive, and Quantitative Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antibodies to Anthrax Toxin Protective Antigen

A CIRCULARLY SYMMETRIC PRIMITIVE EQUATION OF TROPICAL CYCLONE DEVELOPMENT CONTAINING WATER VAPOR CYCLE

The LDL Receptor-Related Protein LRP6 Mediates Internalization and Lethality of Anthrax Toxin

Tracking and Structural Vibration Control of Flexible Ball–Screw Drives With Dynamic Variations

Recombinant Anti-Botulinum Neurotoxin A Single-Chain Variable Fragment Antibody Generated Using a Phage Display System

Anthrax lethal toxin: a weapon of multisystem destruction

A Novel Approach to Development of Monoclonal Antibodies Using Native Antigen for Immunization and Recombinant Antigen for Screening.

Targeting Bacillus Anthracis Toxicity with a Genetically Selected Inhibitor of the PA/CMG2 Protein-Protein Interaction

Anti-Acinetobacter baumannii single-chain variable fragments show direct bactericidal activity

LETHAL TOXIN NEUTRALIZING ANTIBODY RESPONSE INDUCED FOLLOWING ORAL VACCINATION WITH A MICROENCAPSULATED BACILLUS ANTHRACIS STERNE STRAIN 34F2 VACCINE PROOF-OF-CONCEPT STUDY IN WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS)

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease